Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients

Phase 3 Unknown 225 enrolled Marqués de Valdecilla Research Institute (IDIVAL)

RandomizedParallel-groupOpen-labelPrevention

Summary

Prospectively evaluation of the incidence of thromboembolic events in hospitalized cirrhotic patients. 2. Efficacy and safety of use of bemiparin in preventing peripheral and portal thrombosis. 3. Monitoring antiXa levels.

Timeline

Start: 2016-05
Primary completion: 2017-06
Completion: 2019-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bemiparin	Other / unclassified	3500 iu	Subcutaneous

Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients

Summary

Timeline

Drugs

Indications